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Abstract: Over the past 20 years, the number of invasive fungal infections has continued to 
  persist, due primarily to the increased numbers of patients subjected to severe immunosuppression. 
Despite the development of more active, less toxic antifungal agents and the standard use of 
antifungal prophylaxis, invasive fungal infections (especially invasive mold infections) continue 
to be a significant factor in hematopoietic cell and solid organ transplantation outcomes, resulting 
in high mortality rates. Since the use of fluconazole as standard prophylaxis in the hematopoietic 
cell transplantation setting, invasive candidiasis has come under control, but no mold-active 
antifungal agent (except for posaconazole in the setting of acute myelogenous leukemia and 
myelodysplastic syndrome) has been shown to improve the survival rate over fluconazole. 
With the advent of new azole and echinocandin agents, we have seen the emergence of more 
azole-resistant and echinocandin-resistant fungi. The recent increase in zygomycosis seen in the 
hematopoietic cell transplantation setting may be due to the increased use of voriconazole. This 
has implications for the empiric approach to pulmonary invasive mold infections when zygomy-
cosis cannot be ruled out. It is imperative that an amphotericin B product, an antifungal that has 
never developed resistance in over 50 years, be initiated. The clinical presentations of invasive 
mold infections and invasive candidiasis can be nonspecific and the diagnostic tests insensitive, so 
a high index of suspicion and immediate initiation of empiric therapy is required. Unfortunately, 
our currently available serologic tests do not predict infection ahead of disease, and, therefore 
cannot be used to initiate “preemptive” therapy. Also, the Aspergillus galactomannan test gives 
a false negative result in patients receiving antimold prophylaxis, ie, virtually all of our patients 
with hematologic malignancy and hematopoietic cell transplant recipients. We may eventually 
be able to select patients at highest risk for invasive fungal infections for prophylaxis by genetic 
testing. However, with our current armamentarium of antifungal agents and widespread use of 
prophylaxis in high-risk groups (hematologic malignancy, hematopoietic cell transplantation), 
we continue to see high incidence and mortality rates, and our future hope lies in reversing the 
immunosuppression or augmenting the immune system of these severely immunocompromised 
hosts by developing and utilizing immunotherapy, immunoprophylaxis, and vaccines.
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Introduction
Invasive fungal infections are a growing problem in our severely immunocompromised 
patients. Hematopoietic cell and solid organ transplantations continue to increase, and 
despite recent development of more active and less toxic antifungal agents, mortality 
rates from invasive fungal infections remain unacceptably high. In this article we review 
invasive fungal infections in immunocompromised hosts. The focus will be on invasive 
mold infections, (particularly invasive aspergillosis) and invasive candidiasis, and on Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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immunocompromised hosts, including neutropenic patients 
with hematologic malignancy, hematopoietic cell transplant 
recipients, solid organ transplant recipients, and high-risk 
intensive care unit patients. Specifically, the following top-
ics will be reviewed: epidemiology, including incidence 
and mortality rates for invasive fungal infections; emerging 
resistance patterns; high-risk groups and risk factors; clini-
cal presentation of each type of invasive fungal infection; 
diagnosis; antifungal treatment options; management; and 
future developments in the treatment and prevention of 
invasive fungal infections.
Epidemiology
The epidemiology of invasive fungal infections has been 
difficult to glean from the literature because of the different 
definitions used, the different risk groups studied, and 
variation from institution to institution. To date, the most 
comprehensive multicenter epidemiologic surveillance study 
of invasive fungal infections in transplantation has been from 
the Transplant-Associated Infection Surveillance   Network 
(TRANSNET) database.1–4 TRANSNET is a   network of 
23 US transplant centers performing hematopoietic cell 
and/or solid organ transplantations. Incidence, clinical and 
diagnostic information, and outcomes such as 12-month 
(and 3-month for hematopoietic cell transplant) mortality 
rates were evaluated.2,4 The database consists of invasive 
fungal infections occurring between 2001 and 2006. Prior 
to this period, the overall incidence of invasive fungal infec-
tion was 18%, based on data from a single US center in a 
placebo-controlled group not on antifungal prophylaxis.5 
According to TRANSNET data, there were 983 proven and 
probable cases of invasive fungal infection in hematopoietic 
cell transplant recipients, comprising of 21% autologous, 
38% matched-related, 34% matched-unrelated, and 6% 
mismatched-related transplants. The overall incidence dur-
ing a 12-month period for invasive fungal infections among 
hematopoietic cell transplant recipients was 3.4% (range 
0.9%–13.2%).2 This lower incidence is likely due to the now 
standard use of antifungal prophylaxis in hematopoietic cell 
transplantation. The incidence of invasive fungal infections 
was lowest for autologous hematopoietic cell transplants 
(1.2%), and increased for matched-related donor (5.8%), 
matched-unrelated donor (7.7%), and mismatched-related 
donor (8.1%). There are 3 phases of hematopoietic cell 
transplantation, ie, phase I (pre-engraftment), phase II 
(postengraftment, ,100 days posttransplant), and phase 
III (late phase, .100 days posttransplant).6 The majority 
of invasive fungal   infections occurred during phase II and 
phase III. TRANSNET data revealed an overall 3-month 
invasive fungal infection mortality rate of 51%.2 The 
12-month mortality rate for overall invasive fungal infection 
was not reported. Other studies have reported the overall 
median 12-month mortality rate to be approximately 80% 
for all invasive fungal infections in hematopoietic cell 
transplantation patients.7
In the TRANSNET database, there were 1063 proven and 
probable cases of invasive fungal infection in solid organ 
transplant recipients.4 The overall incidence of invasive 
fungal infection was 3.1% in a 12-month period, similar 
to that for hematopoietic cell transplantation.4 Historically, 
the incidence has ranged from 5.6% to 10.9%,8 and varies 
according to transplant type.9 The highest incidence for fungal 
infections was with liver transplant (7%–42%), followed by 
pancreas (18%–38%), heart and heart-lung (15%–35%), and 
the lowest with kidney transplant (0%–14%).9 The addition of 
antifungal prophylaxis has lowered the incidence of invasive 
fungal infection in solid organ transplantation. In comparison 
with the older studies, the more recent TRANSNET data 
demonstrated small bowel transplants as having the highest 
risk of invasive fungal infection at 11.6%, followed by lung 
and heart-lung transplants 8.6%, liver 4.7%, and pancreas and 
pancreas-kidney 4%.4 Heart transplant recipients had a lower 
risk at 3.4%, and kidney had the least risk at 1.3%. The major-
ity of invasive fungal infections occurred more than 90 days 
posttransplant. Overall 12-month mortality for invasive fun-
gal infection was not presented in the TRANSNET data.
Currently there are no large multicenter, prospective, 
surveillance studies in nontransplant patients with hemato-
logic malignancy, such as acute myelogenous leukemia and 
myelodysplastic syndrome. However, data are available from 
prophylactic trials.10,11 The incidence of invasive fungal infec-
tions was 2%–8% depending on the antifungal prophylaxis 
regimen used.10,11 Comparison with older studies is difficult. 
The data from clinical trials varies due to the different defi-
nitions of invasive fungal infection. One prophylactic study 
reported invasive fungal infection rates of 20% (proven and 
probable cases) in the placebo arm12 and 4.4% (proven deep-
seated invasive fungal infections) in another study.13 In the 
latter study, the 2-month mortality rate for invasive fungal 
infection was 56%.13 In a recent clinical trial,10 mortality 
for invasive fungal infection was not evaluated. However, 
overall 100-day mortality was evaluated, and was 22% in a 
fluconazole / itraconazole prophylaxis group and 14% in a 
posaconazole prophylaxis group.10
The overall incidence of invasive fungal infections in 
prospective surveillance data that directly compare high-risk Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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groups is limited, and may differ by institution. Autopsy data 
are available from a single-center review (2707 of 10,151 
patients) for 1993–2005.14 Patients with the following under-
lying diseases were included: hematologic malignancy, solid 
tumors, transplant (either solid organ or hematopoietic cell 
transplantation), acquired immunodeficiency syndrome, and 
other diagnoses. Overall, the prevalence of invasive fungal 
infections was 8.2%. Invasive fungal infection rates were 
tabulated by time periods in order to evaluate trends, and 
were as follows: 1993–1996 (6.6%), 1997–2000 (8.6%), 
and 2001–2005 (10.4%). The highest prevalence was found 
in patients with hematologic malignancy (33%), followed by 
transplant (22.9%), acquired immunodeficiency syndrome 
(19.7%), solid tumors (4.8%), followed by other diagnoses 
(3.5%). The most common infecting fungal organisms were 
Aspergillus species, then Candida species. Other fungal 
organisms (eg, Cryptococcus species and Zygomycetes) were 
all found in approximately 1% or less of the cases reviewed. 
The study did note that the prevalence of invasive fungal 
infection decreased over time in the transplant group when 
comparing the 1997–2000 and 2001–2005 periods. As noted 
earlier, this is most likely attributable to the use of antifungal 
prophylaxis in the transplant population.
Aspergillosis
During the 1990s, in patients who did not receive antifungal 
prophylaxis, invasive fungal infections caused by Candida 
species were most frequent (18%), followed by invasive 
fungal infections caused by Aspergillus species (1.4%).5 
This pattern has changed over the past two decades. The 
introduction of fluconazole prophylaxis, which prevented 
many infections caused by Candida species, altered the 
epidemiology of invasive fungal infection. According to 
TRANSNET data, the overall incidence of invasive asper-
gillosis is 1.6%.2 However, invasive aspergillosis is now the 
most common invasive fungal infection in hematopoietic cell 
transplantation (43%, Table 1). Aspergillus fumigatus was the 
most common Aspergillus species (44%).2 The median time 
to infection occurred at the end of the late posthematopoietic 
cell transplantation phase II (day 99). In the solid organ trans-
plantation group, the incidence of invasive aspergillosis was 
0.7%, and accounted for 18.8% of invasive fungal infections 
in the solid organ transplant group.4 It was most frequent in 
lung transplant (44%), whereas it was the second or third most 
frequent invasive fungal infection in other transplant types 
(5%–23%). The median time to onset of invasive aspergillosis 
was 184 days. For nontransplant patients with hematologic 
malignancies, data from antifungal prophylaxis clinical trials 
reported an incidence for invasive aspergillosis of 1%–7% 
with azole prophylaxis10 and 4%–5% with prophylaxis using 
amphotericin B lipid formulations.10,11 The majority of inva-
sive fungal infections were also due to invasive aspergillosis 
(33%–69%). In critically ill patients, the infection rate for 
invasive aspergillosis has been reported to be 2.6%, and the 
proportion of invasive fungal infections caused by invasive 
aspergillosis was 11%.15
Similar to the changing epidemiology of invasive fungal 
infections over recent years, mortality rates have also changed. 
The 3-month overall invasive aspergillosis mortality rate had 
been 42% with conventional amphotericin B,16 and 68% in 
hematopoietic cell transplantation.7 The 1-year mortality rates 
in hematopoietic cell transplantation associated with invasive 
aspergillosis during the 1990s was 80%.7 The 12-month 
mortality rates for transplant patients in the most recent 
TRANSNET data were 75% for hematopoietic cell trans-
plantation and 41% for solid organ transplantation.2,4 Another 
TRANSNET data report indicated 3-month mortality rates 
for hematopoietic cell transplantation of 57.5% (239/415) 
and for solid organ transplantation of 34.4% (78/227).1 The 
same report by TRANSNET did evaluate mortality rate over 
time.1 Mortality rates in hematopoietic cell and solid organ 
transplant recipients were shown to decrease over time from 
approximately 72% and 43% in 2001 to 55% and 27% in 
2005–2006, respectively. Allogeneic hematopoietic cell 
transplantation, neutropenia, cytomegalovirus disease, renal 
or hepatic insufficiency, and corticosteroid use were associ-
ated with higher mortality rates.1 The species of Aspergillus 
also plays a role in mortality. A. fumigatus was associated 
with a 63% 3-month mortality rate compared with Aspergillus 
terreus, a much more antifungal-resistant species, with 
a reported mortality rate of 100%.17
Invasive candidiasis
The epidemiology of invasive candidiasis has also changed. 
In the 1990s, the incidence of invasive candidiasis was 
reported at one institution to be 15%, and accounted for 
88% of all invasive fungal infections in hematopoietic cell 
Table 1 Proportion of invasive fungal infections reported in the 
literature
IA Zygomycosis IC Other Reference(s)
HCT 43% 8% 28% 15% 2
SOT 18.8% 2.3% 52.9% 19% 4
HM 33%–69% – 13.5%–44% – 10,11
iCU 11% – 79% 10% 15
Abbreviations:  HCT,  hematopoietic  cell  transplantation;  HM,  hematologic 
malignancy; iA, invasive aspergillosis; iC, invasive candidiasis; iCU, intensive care unit; 
SOT, solid organ transplantation.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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transplantation.5 In the most recent data from TRANSNET, 
this proportion has changed. The incidence of invasive 
  candidiasis is now 1.1% for hematopoietic cell transplantation 
and just under 2% for solid organ transplantation.2,4 
In hematopoietic cell transplantation and lung transplantation, 
invasive candidiasis is the next largest proportion of invasive 
fungal infections after invasive aspergillosis, at 28% 
and 23%, respectively.2,4 In solid organ transplantation, 
approximately half (52.9%) of invasive fungal infection cases 
were invasive candidiasis.4 Invasive candidiasis made up the 
highest proportion of invasive fungal infections across the 
remaining transplant types. Invasive candidiasis generally 
occurred in the posthematopoietic cell transplantation 
engraftment phase II (day 61), earlier than the onset of 
other invasive fungal infections. Similar to hematopoietic 
cell transplantation, the onset of invasive candidiasis in 
solid organ transplantation followed a similar pattern, 
with an earlier median onset (103 days)   posttransplant 
compared with other invasive fungal infections. The data 
from clinical trials for patients with hematologic malignancy 
demonstrated invasive candidiasis incidences of 1%–3%, and 
invasive candidiasis comprised the next largest proportion 
of invasive fungal infections (13.5%–44%) after invasive 
aspergillosis.10,11 Breakthrough Candida infections on anti-
fungal prophylaxis reported in the literature are of importance 
to the changing epidemiology of invasive candidiasis. 
Micafungin prophylaxis has been associated with invasive 
candidiasis caused by Candida parapsilosis.18
Critically ill patients in intensive care are at an increased 
risk of invasive candidiasis.19–21 In the intensive care unit, 
invasive candidiasis is the third most common cause of infec-
tions globally (17%), and the second most common cause in 
the US (18.2%) after infections caused by Staphylococcus 
aureus (26.9%).15 The proportion of invasive fungal 
infections caused by Candida species was 79%. In the US, 
Candida species are also the third most common cause of 
catheter-related blood stream infections.22 C. albicans is 
the most common Candida species (50%–60%), followed 
by C. glabrata (15%–20%), C. parapsilosis (10%–20%), and 
C. tropicalis (6%–12%), and the remainder are made up by 
C. krusei, C. guillermondii, and C. lusitaniae (1.3%).19
Historically, 3-month mortality due to invasive can-
didiasis was at least 50% in critically ill patients.23 In more 
recent data, the reported 2-month mortality was 42.6%.24 The 
12-month mortality in hematopoietic cell transplantation was 
66.4%2 and 34% in solid organ transplantation.4 Outcomes 
also differed with Candida species. The overall 3-month 
mortality among all patients with invasive candidiasis 
ranged from highest with C. krusei (52.9%) to lowest with 
C. parapsilosis (23.7%).21
Zygomycosis
According to TRANSNET data, the proportion of inva-
sive fungal infections caused by zygomycosis is 8% in 
hematopoietic cell transplantation2 and 2.3% in solid organ 
transplantation.4 The incidence in hematopoietic cell and 
solid organ transplantation was approximately 0.3% and 
0.1%, respectively.2,4 Most infections occurred after day 100 
after posthematopoietic cell transplantation and at median 
day of 312 postsolid organ transplantation. The overall 
3-month and 12-month mortality rates in hematopoietic 
cell transplantation were approximately 64%–72%.2,25 
There is also an increasing rate of zygomycosis infection 
in hematopoietic cell transplantation recipients.3 In 2001, 
the 1-year incidence of zygomycosis was 1.7/1000 patients. 
In 2004, it increased to 6.2/1000 patients. Another study 
found similar results with the advent of newer antifungals, 
such as voriconazole and caspofungin, correlating with 
significant increases in zygomycosis.26 The rates increased 
from 0.57/100,000 admissions prior to 2003 to 6.3/100,000 
admissions after 2003. These increasing trends likely cor-
relate with recent reports of breakthrough infections in 
those receiving prophylaxis with newer antifungals, such 
as voriconazole and echinocandins, in hematopoietic cell 
transplantation.26–29
Other invasive fungal infections
Other invasive fungal infections in the transplant population 
occur less frequently than invasive aspergillosis, invasive 
candidiasis, and zygomycosis. In the hematopoietic cell 
transplantation population, the incidences for non-Aspergillus 
and unspecified mold were approximately 0.3% and 0.2%, 
respectively.2 The proportion of invasive fungal infec-
tions caused by Fusarium species was 3%. Acremonium, 
Alternaria, and Scedosporium species accounted for 7%. 
Unspecified molds accounted for 6% of invasive fungal infec-
tions. The majority of these infections occurred after day 100 
posthematopoietic cell transplantation.2 In the solid organ 
transplantation population, the incidences were 0.1%–0.2% 
for other molds and endemic invasive fungal infections. 
Cryptococcus infections comprised 8% of all invasive fungal 
infections, and other molds comprised 6.5%. Endemic fungal 
infections comprised 5.3% of all invasive fungal infections.4 
In intensive care patients, infections caused by other fungi 
occurred at a rate of 2.2%, representing 10% of all invasive 
fungal infections.15Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Mortality rates for molds other than Aspergillus species 
and Zygomycetes vary according to pathogen. The highest 
mortality rate is seen with fusariosis in hematopoietic cell 
transplantation (93.7%).2 The 12-month mortality among 
solid organ transplant recipients was 39% for other molds, 
and 27% for Cryptococcus.4 Other studies have reported 
3-month mortality rates of 80% in hematopoietic cell trans-
plantation from infections due to Fusarium and Scedospo-
rium species.25
Resistance and trends
The potential for increasing antifungal resistance has long 
been a concern in the treatment of invasive   fungal infections. 
Fungal pathogens can exhibit various mechanisms of resistance. 
The most common for antifungals are target mutations or 
change in expression of genes, such as overexpression of the 
efflux pumps that remove antifungals.30,31
Candida and resistance
Azole resistance was first noted in Candida species in patients 
with acquired immunodeficiency syndrome.32 There was a 
total of 348 isolates tested against fluconazole, and 33% were 
found to be resistant compared with 11% in isolates from 
patients without acquired immunodeficiency syndrome. This 
was related to prolonged exposure and use for such condi-
tions as Candida esophagitis. A similar concern exists for 
transplant and other immunocompromised patients because 
they may be exposed to prolonged use of azole antifungal 
agents as well.33
Overexpression of efflux genes is the most common 
mechanism of resistance to azoles in Candida species, and 
has also been associated with cross-resistance within the 
class.30,31 Progressive loss of echinocandin activity has been 
observed in Candida species when exposed to prolonged 
echinocandin use.34 The most common mechanism of echi-
nocandin resistance is associated with mutation in the FKS1 
gene, a gene that produces the FKS1 protein for β-1,3-D-
glucan synthase.
Aspergillus and resistance
Similar to Candida species, the mechanism of resistance 
in molds, such as Aspergillus species, is due to point 
mutations and efflux pump overexpression; however, the 
targets are different.34 The CYP51 gene (important for 
encoding 14-α-sterol demethylase) target mutation results 
in decreased azole susceptibility,34,35 and may lead to cross-
resistance between itraconazole and posaconazole, but not for 
echinocandins.34 Overexpression of multidrug-resistant efflux 
pumps confers decreased susceptibility in A. fumigatus,36 and 
has been shown to be inducible with voriconazole treatment 
in a mouse biofilm model.
Resistance patterns
Overall susceptibility patterns have also been changing 
over time due to use of prophylactic antifungal agents. 
In a large collection of 519 A. fumigatus isolates, resis-
tance to azoles increased between 1997 and 2007.37 
There was no resistance found in isolates from 1997, 
and only 3%–7% resistance in the years prior to 2004. 
Between 2004 and 2007, resistance increased each 
year to 17% in 2007. Each year after 2004, multiazole 
resistance increased. In another study, the epidemiology 
of 269 oral Candida isolates was evaluated in patients 
with hematologic malignancies, and in those with head 
and neck and solid tumors.38 C. albicans comprised 
the majority (74%) of isolates. Resistance patterns for 
azoles were as follows: fluconazole 4.5% (C. albicans, 
C. glabrata, C. krusei), itraconazole 11.7% (C. albicans, 
C. glabrata, C. tropicalis), and voriconazole 0.75% 
(C. glabrata). Resistance to caspofungin was 4.1% 
(C. albicans, C. parapsilosis) and 10.2% had intermediate 
susceptibility. None were resistant to amphotericin B.
High-risk groups
Immunocompromised patients at highest risk for develop-
ing invasive fungal infection include hematopoietic cell 
transplant recipients, solid organ transplant recipients, 
patients with hematologic malignancy, and patients with 
other severe immunologic conditions. In hematopoietic cell 
transplant recipients, there are 3 phases of risk for invasive 
fungal infections.6 Phase I is marked by neutropenia and 
barrier breakdown. In phase II, patients are at risk for inva-
sive fungal infections due to impaired cellular immunity. 
Although CD8 T cells are increasing postengraftment, 
specific antifungal T cell immune reconstitution is not 
complete until months to a year after hematopoietic cell 
transplantation.39 Acute graft versus host disease and its 
treatment with corticosteroids are the major contributors 
to the risk of invasive fungal infection during this phase. 
In phase III, chronic graft versus host disease and corticos-
teroid therapy remain significant risk factors for continuing 
impaired cellular immunity.
Solid organ transplant recipients are at increased risk 
of invasive fungal infection due to the long-term immu-
nosuppressive therapies that may be required to prevent or 
treat rejection.40 In solid organ transplantation, periods of Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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infection risk posttransplant have also been noted. During 
the early posttransplant period (1 to 2 months), Aspergillus 
pneumonia can occur. Up to 6 months posttransplantation, 
chronic rejection is a risk factor for invasive fungal infections. 
Subsequently, beyond six months posttransplantation, the risk 
is mainly due to residual immunosuppression, exposure to 
T   cell-depleting agents, and graft function.
For patients with hematologic malignancy, the main risk 
factor is prolonged neutropenia after immunosuppressive 
chemotherapy, such as induction, reinduction, and consolida-
tion chemotherapy.10,41,42 For critically ill patients, the main 
risk factors include severe disease and long-term stay in an 
intensive care unit.20
Risk factors
There are risk factors specific for each invasive fungal infection 
(Table 2). Risk factors for invasive aspergillosis include graft 
versus host disease, corticosteroids, neutropenia, cytomegalo-
virus infection, and prior lung disease. Risk factors for invasive 
candidiasis include neutropenia, central venous catheter, total 
parental nutrition, corticosteroids,   gastrointestinal surgery, 
prolonged intensive care stay, and broad spectrum antibiotics. 
These risk factors relate to impairment of the host immune 
system, genetic predisposition, and environmental exposure.
Host/immune system
It has long been observed that the longer and more profound 
the neutropenia, the more at risk the patient will be for inva-
sive fungal infections.43 Circulating neutrophils have been 
demonstrated to have an inverse relationship with prevalence 
of infections.44,45 The duration of neutropenia was found to 
be the most important factor, especially when persisting for 
3 weeks or more.43,44 In addition to risk for invasive fungal 
infections, recovery of neutrophil count is important in 
patient outcomes.
invasive aspergillosis
One study found that risk factors varied slightly depending on 
when infection occurred, ie, within 40 days or after 40 days 
posthematopoietic cell transplantation.46 Risk factors related 
to the host that were similar for both early and later onset of 
infection were underlying disease, donor type (autologous , 
matched-related , matched-unrelated , mismatch-related), 
and graft versus host disease. There were additional host 
immune factors found for infection risk 40 days posttrans-
plant, ie, neutropenia and corticosteroid use. However, it is 
often difficult to determine if the risk of invasive aspergillosis 
is due to graft versus host disease itself or due to the corticos-
teroids used to treat the graft versus host disease. Compared 
with patients who did not have invasive aspergillosis, patients 
with hematologic malignancy in “non-first remission” were 
8.9 times more at risk for onset of infection within 40 days 
posthematopoietic cell transplantation, and 3.06 times more 
at risk 40 days posttransplant. Mismatched-related donor 
hematopoietic cell transplantation has a significantly higher 
risk in the early posttransplant period, whereas after 40 days, 
the risk is higher with unrelated donor transplants. For inva-
sive aspergillosis, the presence of graft versus host disease 
grades 2–4 had a relative risk of 2.6, neutropenia 5.9, and 
corticosteroid use 3.1.
Other studies have reported similar findings with regard 
to risk factors for invasive fungal infection.47 Myelody  splastic 
  syndrome compared with other underlying hematologic   diseases 
(including acute myelogenous leukemia, chronic myelogenous 
leukemia, acute lymphocytic leukemia, and multiple myeloma) 
and unrelated donor hematopoietic cell transplantation 
compared with sibling donor transplantation were significant 
risk factors for invasive fungal infection. Grades 3–4 acute 
graft versus host disease and extensive chronic graft versus 
host disease were also found to be significant risk factors.47,48 
T cell-depleting therapies (antithymocyte globulin or alemtu-
zumab) delay immune recovery and also increase the risk of 
invasive aspergillosis.6,48–51
Table 2 Risk factors for invasive fungal infections
Risk factors
iFi Host predisposition
Neutropenia 3 weeks
Environmental factors
iA GvHD (acute grades 2–4 or chronic)
HCT type (mismatched-related donor at greatest risk)
Underlying hematologic disease (MDS or AML)
Corticosteroid (dose and duration)
T cell-depleting therapy
CMv infection
Ganciclovir use
Polymorphisms (TLR4, TNF, or iL-10)
HCT in nonlaminar air flow room
iC Colonization
Presence of central venous catheter
Hemodialysis
Surgery (complicated or repeated abdominal)
Clinical unstable presentation (acute renal failure, shock, 
disseminated intravascular coagulation)
Antianerobic antibiotic agents
Total parental nutrition or intralipid agents
Prolonged iCU stay
Abbreviations: AML, acute myelogenous leukemia; CMv, cytomegalovirus; GvHD, 
graft versus host disease; HCT, hematopoietic cell transplantation; HM, hematologic 
malignancy; iA, invasive aspergillosis; iC, invasive candidiasis; iCU, intensive care unit; 
iFi, invasive fungal infection; iL-10, interleukin-10; MDS, myelodysplastic syndrome; 
SOT, solid organ transplantation; TLR4, toll-like receptor 4; TNF, tumor necrosis 
factor.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
181
invasive fungal infections
Chronic treatment for graft versus host disease with 
corticosteroids places hematopoietic cell transplantation 
recipients at increased risk of infection. Risk was found to 
be associated with the duration and intensity of the corticos-
teroid regimen.52 The greatest risk for infection was found 
to be within 2 weeks of high prednisone-equivalent doses of 
1 mg/kg/day or greater. This extended to 4 weeks for doses 
of 0.25–1 mg/kg/day. Other immunosuppressants, such as 
daclizumab and infliximab, have been significantly associated 
with invasive fungal infection.53,54
Cytomegalovirus infection has been associated with 
risk for invasive fungal infection.49,52 The virus itself is 
marrow-suppressive, as is the drug therapy commonly used 
to treat cytomegalovirus, ie, ganciclovir. Cytomegalovirus 
suppresses cellular and humoral immunity, causes abnormali-
ties in lymphocytes and monocytes, and suppresses antigen-
specific cytotoxic T lymphocytes.49 Ganciclovir (an antiviral 
agent with marrow-suppressive effects) has been associated 
with a significant risk for invasive aspergillosis, with a hazard 
ratio of 13.5, even higher than the use of high-dose corticos-
teroids, graft versus host disease, or neutropenia.52
Genetic predisposition
The study of genetic risk factors as they relate to development 
of invasive fungal infection is becoming increasingly impor-
tant to evaluate. This is not only to select those patients who 
are at high risk for invasive fungal infection for prophylaxis, 
but to illuminate the immunology and pathophysiology of 
invasive fungal infections. Invasive aspergillosis has been 
studied the most in this regard. Polymorphisms in toll-like 
receptors (TLRs) and tumor necrosis factor (TNF)-α are 
considered to be one of the more significant genetic factors 
associated with infection.55,56
TLRs are immune cell surface proteins that recognize 
fungal pathogens. TLR polymorphisms have been associ-
ated with different types of infections.57 Two donor TLR4 
haplotypes, S3 and S4, were found to have increased risk 
for invasive aspergillosis, with hazard ratios of 2.2 and 6.2, 
respectively.55
TNF-α is secreted by macrophages and activated T lym-
phocytes during fungal infection.56 TNF-α acts through TNF 
receptor 1 (TNFR1) to trigger a proinflammatory response. 
Single nucleotide polymorphisms in the TNFR1 gene have 
been associated with susceptibility to invasive aspergillosis, 
with odds ratios of 1.7–1.9. It was demonstrated that signifi-
cantly lower TNFR1 mRNA expression occurred in patients 
with invasive aspergillosis compared with noninfected 
patients with single nucleotide polymorphisms in TNFR1.
Single nucleotide polymorphisms in the proximal region 
and haplotypes of the interleukin (IL)-10 promoter gene 
have also been evaluated. IL-10 is a typical Th2 regulator 
cytokine.58 Increased production of IL-10 has been shown to 
be associated with invasive aspergillosis. Thus, single nucle-
otide polymorphisms may affect transcription of IL-10 genes 
and thus production of IL-10, as would certain haplotypes. 
One study found an increased incidence of invasive asper-
gillosis with increased occurrence (11.5–19.7%)58 of single 
nucleotide polymorphisms, with a hazard ratio of 9.3.
Environmental factors
Environmental factors can play a role in the risk of inva-
sive fungal infection in high-risk patients. In regards to 
hematopoietic cell transplantation, it was found that trans-
plants that occurred outside laminar air flow rooms had 
an increased risk of invasive aspergillosis during the early 
posthematopoietic cell transplantation period, within 40 days 
after transplant.46 The risk for infection was 5.6 times higher 
than for transplants occurring within a laminar air flow room. 
For infections occurring beyond 40 days posttransplant, 
environmental factors were also found to be significant. 
This is important because most hematopoietic cell transplant 
recipients are discharged from the hospital (and their HEPA 
[Health Enhancing Physical Activity]-filtered environment) 
by day 40 when they are at high risk for invasive mold infec-
tion. Hence, this may explain the peak incidence of invasive 
aspergillosis that was observed at day 99 in the recent 
TRANSNET data.2 Construction placed patients at higher 
risk for infection by 1.8 times.46 Seasonality can also play 
a role in the risk of invasive fungal infection.46 One study 
found the summer months to be associated with the highest 
risk for invasive aspergillosis.59
invasive candidiasis
Another high-risk group for fungal infections is critically ill 
patients. These patients are mainly at increased risk of inva-
sive candidiasis. There are multiple risk factors that have been 
associated with invasive candidiasis, ie, colonization, pres-
ence of a central venous catheter, hemodialysis, and surgery, 
particularly complicated and repeated abdominal surgery.20,60 
Patients who are clinically unstable are at increased risk 
for invasive candidiasis, ie, those with acute renal   failure, 
shock, and disseminated intravascular coagulation.60   Certain 
medications have been associated with increased risk for 
candidemia. These include antianerobic antibiotics (2.2 rela-
tive risk) such as carbapenems, metronidazole, clindamycin, 
and piperacillin/tazobactam. However, there was no increased Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
182
Kriengkauykiat et al
risk with individual antibiotics, such as aminoglycosides, 
cephalosporins, and quinolones. Of those patients who did 
not receive an antibacterial antibiotic, none developed can-
didemia. This is likely related to replacement of the normal 
gastrointestinal flora with Candida species. Other agents 
associated with invasive candidiasis are parenteral nutrition 
and intralipid agents.
Clinical presentation of invasive 
fungal infections
Manifestations of invasive fungal infection in the immuno-
compromised host may range from fever of unknown etiology 
to symptoms and signs referable to a specific organ system 
affected by the fungal pathogen.61 At the other end of the 
spectrum are patients with no symptoms or signs, primarily 
due to the underlying immunosuppression, steroid use, and 
neutropenia.62,63
Candidemia and visceral  
(chronic disseminated) candidiasis
Fever persisting despite appropriate empiric antibacterial 
therapy during neutropenia is one of the most common mani-
festations of candidemia in immunocompromised patients; 
up to 88% of episodes in one series64 and 99% in another.65 
Sepsis syndrome/septic shock can be an initial presentation 
of candidemia with multiorgan dysfunction. Skin and soft 
tissue involvement usually manifests as a rash that may have 
a variable presentation, ranging from maculopapular ery-
thematous to nodular lesions, and may be painful. The lesions 
may appear similar to ecthyma gangrenosum.66 Muscle pain/
myositis may be present. Candida endophthalmitis may be 
asymptomatic (depending on location of lesions), but may 
manifest with blurred vision, creamy white retinal lesions 
that may evolve to retinal necrosis evident on funduscopic 
examination. Vitritis and uveitis can be seen.67 Cardiac 
involvement can be in the form of infective endocarditis 
of a native or prosthetic valve, pericarditis,68 and septic 
thrombophlebitis, usually in the setting of indwelling central 
venous catheters.
Candidemia can be associated with dissemination to 
deep organs causing visceral (chronic disseminated) candidi-
asis, identified most commonly in the setting of resolving 
  neutropenia after cytotoxic chemotherapy in acute leukemia 
and hematopoietic cell transplantation. This syndrome is 
associated with a low yield of fungal isolates on blood 
culture. With resolution of neutropenia, the patient may 
present with fever, right upper quadrant pain, palpable tender 
hepatomegaly, and elevated serum alkaline phosphatase. 
Diagnosis is often pursued based on a prior episode of 
documented candidemia. Other organs that are affected 
include the spleen and kidneys.69 In a prospective study, 2019 
episodes of candidemia were identified.21   Distribution of the 
organs involved in those determined to have disseminated 
disease were abdomen in 95 (53%), lungs in 17 (9.5%), 
skin and soft tissue in 14 (7.8%), eyes in nine (5%), heart 
in seven (3.9%), tracheobronchial tree in seven (3.9%), 
skeleton in three (1.7%), and central nervous system in 
two (1.1%). Lung involvement is rare, but is manifested as 
innumerable nodules on imaging, usually in conjunction with 
dissemination to other sites, and is mostly asymptomatic. 
Skeletal involvement can manifest as vertebral osteomyelitis/
discitis, and commonly manifests with progressive back pain 
and a relative lack of constitutional symptoms.70 Central 
nervous system involvement can be in the form of meningitis 
or brain abscess.
invasive mold infections
The most common clinical presentation of invasive mold 
infection is pneumonia, with Aspergillus species being the 
leading cause in patients with hematologic malignancy, 
hematopoietic cell transplantation (especially in association 
with graft versus host disease and corticosteroid therapy), 
and solid organ transplantation. The classic symptoms 
include fever, cough, pleuritic chest pain, and, at times, 
hemoptysis,61 and on examination there may be a pleural 
rub. All of these symptoms are rarely present simultaneously. 
Aspergillus tracheobronchitis is seen more frequently in 
lung transplant recipients.71 Non-Aspergillus septated mold 
infections (Scedosporium, Fusarium, and Acremonium 
species), and Zygomycetes may also present in a similar 
manner. Invasive sinusitis can manifest as headache/sinus 
pain, nasal stuffiness with or without discharge, fever, ptosis, 
proptosis, and cranial nerve deficits. Rapidly progressive 
disease may be suggestive of zygomycosis. The nasal exami-
nation may reveal a grayish discoloration of the mucosa early 
on, and necrotic turbinates or eschar later on. Intracranial 
extension of invasive sinusitis can result in central nervous 
system infection, manifesting as brain abscess, cavernous 
sinus thrombosis, and meningitis. Central nervous system 
infection may result from hematogenous dissemination with 
vascular thrombosis and infarction.72 The angioinvasive 
molds have a propensity to cause brain abscesses.73 The 
sudden appearance of mental status changes and/or focal 
neurologic deficits should alert one to central nervous sys-
tem involvement. Other manifestations include skin lesions 
in the setting of disseminated infection (such as Fusarium Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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species, Acremonium species, Aspergillus species, and 
Zygomycetes), ocular involvement (endophthalmitis with 
blindness), osteoarticular infections, and uncommonly, 
gastrointestinal involvement.
Diagnosis
The diagnosis of invasive fungal infections can be challeng-
ing, especially when associated with protean manifestations. 
The European Organization for Research and Treatment of 
Cancer/Mycoses Study Group74 diagnostic criteria are used 
primarily for research purposes, but can be applied in clini-
cal practice. Currently, diagnosis relies upon the presence 
of risk factors (host characteristics, ie, underlying disease, 
immunosuppressive regimen, and transplantation), micro-
biology, serologic testing (AGM and β-1,3-D-glucan assay 
[BDG]), and imaging. The gold standard for establishing 
proven infection is to obtain tissue for histologic or cultural 
confirmation of invasive disease.
Candidemia/visceral candidiasis
Culturing of blood is readily available but lacks sensitivity 
(ranging between 50% and 70%), which may be enhanced 
by cell centrifugation. For visceral candidiasis, a high index 
of clinical suspicion should lead to a diagnostic workup that 
would include imaging. The yield of a positive blood culture 
is poor in visceral invasive candidiasis, with candidemia 
detected in only 20%–30% of cases.70,75 Imaging (computed 
axial tomography [CT], ultrasonography, and magnetic reso-
nance imaging [MRI])76 can be suggestive of this condition 
(hypodense lesions in liver, spleen, kidneys, and lungs). The 
pattern of radiographic abnormality suggesting different 
stages of infection has been described with ultrasonogra-
phy, CT, and MRI.77 MRI may be more sensitive than CT 
for detection of lesions and staging of disease.76 Biopsy of 
the suspected lesion should be attempted, if feasible, for a 
definitive diagnosis, although sampling error is possible. 
BDG is an adjunctive test that can be useful, with sensitivity 
and specificity reported at .90% in invasive candidiasis.78,79 
It can also be positive in a number of other invasive fungal 
infections (such as aspergillosis and fusariosis). Another 
issue with BDG is the high rate of false positive results. 
Various other antibodies and antigens, along with polymerase 
chain reaction, have been studied but have not been approved 
for clinical use.
invasive mold infections
The diagnosis of invasive mold infection can be problem-
atic and is often delayed due to the presence of nonspecific 
symptoms. CT scan of the chest is often the first diagnostic 
test, and should be performed promptly in those suspected 
to have pneumonia due to invasive mold infection. The 
radiographic appearance can be quite variable, from the 
solitary nodule with a halo sign to later consolidation (with 
or without cavitation, air crescent sign).80,81 It can also pres-
ent just with diffuse infiltrates. The findings in zygomycosis 
can be similar, with a propensity to invade through the chest 
wall or extension through fissures. Radiographic findings due 
to molds other than Aspergillus species and Zygomycetes 
tend to be similar. Therefore, the specific fungal species 
causing the infection cannot be determined by radiographic 
appearance, and there is a need for further evaluation. 
Bronchoscopy with lavage, serologic testing (AGM, BDG), 
CT-guided biopsy of infiltrate, and open lung biopsy should 
be considered in sequence.
CT scan of the paranasal sinuses and orbits should be 
considered in those presenting with sinonasal symptoms. 
Endoscopic sinonasal examination with biopsies for micro-
biologic and histologic examination should be performed 
as necessary without delay. In situations where central ner-
vous system disease is suspected, CT or MRI of the brain 
should be obtained, in conjunction with an assessment of the 
sinuses. The finding of a focal lesion suggestive of abscess 
or disseminated fungal infection, warrants consideration of 
a biopsy if feasible, unless there is another site proven to be 
involved. Cerebrospinal fluid should be sampled (if there are 
no contraindications) for diagnostic microbiologic, cytologic, 
antigen, and nucleic acid testing for invasive fungal infection 
and other opportunistic organisms.
Mold fungemia with positive blood cultures is observed 
frequently with infection due to Fusarium, Acremonium, and 
Scedosporium species, but rarely, if ever, with Aspergillus 
species. Skin is often involved, with multiple painful necrotic 
lesions, with Fusarium and Acremonium species,82,83 while 
lesions with Scedosporium are usually painless.
Serologic tests have been an important development as 
an adjunct in the diagnosis of invasive fungal infections. 
AGM and BDG have been incorporated into the European 
Organization for Research and Treatment of Cancer/
Mycoses Study Group criteria for diagnosis of fungal 
infection. The AGM test has low sensitivity in the setting 
of antimold prophylaxis,84 rendering its utility in acute 
myelogenous leukemia/myelodysplastic syndrome and 
hematopoietic cell transplantation uncertain, and therefore 
cannot be used as a screening test for preemptive therapy. 
The application of AGM and BDG in the diagnosis of inva-
sive aspergillosis was recently reviewed.85 Polymerase chain Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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reaction for diagnosis of invasive mold infection appears 
promising, but due to lack of standardization/validation, 
remains investigational.
Antifungal agents
Systemic antifungal agents available for the treatment of 
invasive fungal infections include the polyenes, azoles, 
echinocandins, and flucytosine (Table 3). The polyene class 
includes amphotericin B products.86 Amphotericin B deoxy-
cholate is the oldest, and with infusion-related side effects. 
Amphotericin B lipid complex, liposomal amphotericin B, 
and amphotericin B colloidal dispersion are lipid formula-
tions developed in an attempt to decrease these side effects. 
However, the latter of these agents is used less frequently 
than the other formulations due to a higher rate of infusion-
related reactions than with amphotericin B deoxycholate. 
Nephrotoxicity is another common adverse effect associated 
with all amphotericin B products. Their spectrum of activ-
ity is broad, and includes Aspergillus species (A. terreus 
is resistant), Zygomycetes, Candida species, and endemic 
fungi.87–89
The azoles used most commonly as systemic therapy 
in invasive fungal infection include fluconazole, itracon-
azole, voriconazole, and posaconazole. All azoles have 
activity against yeast such as Candida species; however, 
fluconazole has no mold activity.90,91 The azoles with 
mold activity are active against Aspergillus species. 
Voriconazole has no activity against Zygomycetes, while 
posaconazole does have activity against Zygomycetes. The 
most common adverse effects of azoles are raised hepatic 
enzymes, QTc prolongation, food-drug interactions, and 
interactions with concomitant drugs that are substrates 
for or alter cytochrome P450 isoenzymes.92 Additionally, 
visual disturbances may occur with voriconazole. Thera-
peutic drug monitoring of azoles (except for fluconazole, 
given its limited drug-drug interactions and predictable 
bioavailability) would be beneficial to ensure adequate 
serum levels.92–95
The echinocandins are the most recent antifungal class, 
and comprise caspofungin, micafungin, and anidulafungin. 
These agents have activity against yeasts, such as   Candida 
species, and molds, such as Aspergillus species.96,97 However, 
activity against other molds, such as Zygomycetes, is 
lacking, and increased tolerance has been observed with 
C. parapsilosis and C. guillermondii.18,98 Echinocandins 
are well tolerated, with few side effects, and they lack renal 
toxicity. Echinocandins can be used in patients with hepatic 
impairment (with dose reduction, as for caspofungin).
Flucytosine is an antimetabolite with in vitro   activity 
against a variety of fungi, most notably Candida and 
  Cryptococcus species.99 It is not used as monotherapy because 
resistance develops readily. Its main use is in combination 
therapy with amphotericin B for invasive candidiasis and 
cryptococcosis.
Table 3 Antifungal agents: uses, pros, and cons
Drug Uses Comments
Polyenes Salvage therapy and empiric use due to broad activity Nephrotoxicity and infusion reactions are the largest 
drawbacks
Fluconazole iC in stable patients or stepdown agents; prophylaxis 
in HCT; no need to monitor blood levels
No mold activity
itraconazole May be used as stepdown therapy where other azoles 
are unavailable or intolerant in iC or invasive 
aspergillosis; should monitor blood levels
Limited usefulness, other agents may be preferred: 
variable oral absorption, food and pH-dependent, side 
effect profile (GI, cardiac, hepatic)
voriconazole First-line therapy in invasive aspergillosis; iC in stable 
patients or stepdown therapy
iv formulation contraindicated in renal impairment  
CrCl # 50 mL/min; side effect profile (rash, visual, hepatic, 
cardiac); DDi; associated emergence of zygomycosis; need 
to monitor blood levels
Posaconazole Prophylaxis in HCT/HM; salvage therapy for iFi  
(eg, zygomycosis)
Absorption dependent on high fat meals; side effect profile 
(hepatic, cardiac although least toxic of azoles after 
fluconazole); oral formulation only; need to monitor  
blood levels
Echinocandins Primary indication for iC; micafungin for prophylaxis in 
HCT; caspofungin for empiric therapy in febrile 
neutropenia; salvage therapy for invasive aspergillosis; 
potential addition for combination therapy; few side 
effects or DDi
Not for primary monotherapy in invasive aspergillosis 
Breakthrough iFi have been seen 
Flucytosine Used in combination with other antifungal agents in iC Marrow toxic; only oral formulation available 
Abbreviations: CrCl, creatinine clearance; DDi, drug-drug interactions; Gi, gastrointestinal; HCT, hematopoietic cell transplantation; HM, hematologic malignancy;   
iA, invasive aspergillosis; iC, invasive candidiasis; iFi, invasive fungal infection.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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invasive aspergillosis
Voriconazole has the best clinical activity against Aspergillus 
and Scedosporium species, and is considered first-line 
therapy for infections caused by these pathogens.16,91,100 
  Amphotericin B products can be used as   second-line agents 
in patients who cannot tolerate or are failing voriconazole 
therapy,101 and echinocandins can be used as alternative or 
salvage therapy.100,102–104
invasive candidiasis
In severe cases of invasive candidiasis, such as in critically ill 
patients, amphotericin B products can be used with or without 
flucytosine.105 Echinocandins are effective against invasive 
candidiasis and are first-line therapy.97,105 Fluconazole and 
voriconazole are good choices for invasive candidiasis or 
stepdown therapy in severe cases of invasive candidiasis or 
candidemia after treatment with an amphotericin B product 
or an echinocandin.105
Zygomycosis and other mold infections
Delay in the use of an amphotericin B product up front 
in zygomycosis has been associated with poor survival 
  outcome.106 Thus, the polyenes should be used first-line 
in invasive fungal infections caused by zygomycosis or 
unknown molds, because they have the broadest spectrum 
of coverage.28 Among the azoles, posaconazole is the only 
azole having activity against Zygomycetes, and has proven 
efficacy as salvage therapy for zygomycosis.91,107–109
Combination therapy
Data for combination antifungal therapy varies depending on 
the invasive fungal infection involved. For invasive candidi-
asis, especially for infections that are deepseated or where 
penetration may be an issue, such as in the central nervous 
system or in endocarditis, an amphotericin B product in 
combination with flucytosine may be used.99,105 This combina-
tion allows for synergy, as well as better penetration into the 
central nervous system, synovial fluid, or valves. Other data 
suggest that combination of fluconazole and amphotericin B 
may be a useful alternative.110
For other invasive fungal infections, data come mainly 
from in vitro studies, animal models, retrospective reviews, 
and case reports. Combination therapy for invasive 
  aspergillosis is more controversial. Many in vitro and in vivo 
studies vary in methodology, but do suggest synergistic or 
additive effects when an echinocandin is combined with an 
amphotericin B product or an azole.111–113 Combinations of 
amphotericin B and an azole can demonstrate antagonism and 
clinical failure if amphotericin B is given after itraconazole,114 
but also indifferent effects when given concurrently.115,116 
Combining three classes (voriconazole, caspofungin, and 
amphotericin B) has shown variable results, depending on 
drug concentrations.117,118 Randomized, controlled studies are 
lacking in the evaluation of combination therapy. However, 
there is a study currently underway evaluating the clinical 
efficacy of voriconazole versus voriconazole plus anidula-
fungin in invasive aspergillosis.
For zygomycosis, data for combination therapy has shown 
some promise when iron chelators, such as deferiprone 
and deferasirox, are used in combination with liposomal 
amphotericin B.119,120 On the other hand, caution must be 
exercised when using other iron chelators, such as deferox-
amine, which has been shown to aggravate zygomycosis by 
making siderophore iron-feroxamine complexes available 
to the pathogen.121 A combination of posaconazole and 
amphotericin B has not demonstrated added benefit.120 Data 
on combination therapy for other invasive mold infections 
are even more limited.
Surgical intervention
In certain situations, surgery may be warranted in order to 
resect the infected focus in invasive mold infection, particu-
larly areas where antifungals have limited penetration. These 
may include solitary pulmonary lesions, invasion of the chest 
wall, osteomyelitis, pericardial infection, endocarditis, or 
fungal balls, such as aspergillomas.100 Other situations where 
surgical intervention may be necessary include debridement of 
infected tissues as in rhinosinusitis, cerebral lesions, infected 
skin and soft tissue, or removal of prosthetic devices, and 
infected vascular catheters.100,105,122 The latter is particularly 
important for candidemia. Candida species form a biofilm 
around catheters, and thus prevent complete eradication 
by antifungal agents alone and are associated with higher 
mortality.123,124 Timing of catheter removal, ie, 24 hours ver-
sus 48 hours, did not demonstrate significant differences in 
outcome, but removal versus no removal did.124
Approaches to management
Different approaches have been described for management of 
invasive fungal infection and have been thoroughly reviewed 
in the literature, and therefore only a brief summary of these 
approaches is described here.125,126 These approaches include 
empiric, “preemptive”, prophylactic, and pathogen-specific 
therapy.125,126
Empiric therapy is an early approach in patients with febrile 
neutropenia, which usually entails starting or adjusting antifun-Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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gal therapy in high-risk patients with unexplained fevers that 
are persistent or recurrent after 4–7 days of antibiotics.127
The preemptive approach is also an early treatment as 
empiric therapy. Preemptive therapy has traditionally been 
applied towards viral infection (ie, cytomegalovirus) where 
treatment is started for evidence (such as polymerase chain 
reaction for viral load) of infection (or viremia) before dis-
ease onset. However, this is not practical for invasive fungal 
infection because there is no preemptive test available. That 
is, there is no diagnostic test that predicts infection ahead of 
disease. Hence, this approach would be better described as 
“empiric” or “presumptive”. Instead, it is based on suspicion 
for an invasive fungal infection that is already established, 
particularly mold infection.125 Suspicion may include sero-
positivity for AGM and supportive radiographic findings 
for invasive fungal infection in high-risk patients, and thus 
antimold agents are started.128
Prophylaxis against invasive fungal infection in 
hematopoietic cell transplant recipients has been shown to 
improve outcomes, such as decreasing invasive fungal infec-
tion rates.5,10,129–131 In hematopoietic cell transplantation, only 
prophylaxis with fluconazole has shown a survival benefit.5,132 
Other antifungals have been compared with fluconazole, 
but none have demonstrated an improved survival benefit 
over fluconazole in hematopoietic cell transplantation.129,131 
However, a survival benefit was demonstrated for posa-
conazole prophylaxis in neutropenic patients undergoing 
chemotherapy for acute myelogenous leukemia or myelo-
dysplastic syndrome.10
Finally, from a practical point of view, the identity of 
the specific pathogen is rarely known. Therefore, a directed 
empirical approach to therapy should be employed using all the 
currently available information.125 When invasive candidiasis 
is suspected, the choice of antifungal agent depends on the cur-
rent clinical presentation of the patient, such as hemodynamic 
stability, prior antifungal exposure, and resistance patterns at 
a particular institution. One may choose an azole, echinocan-
din, or amphotericin B product ± flucytosine depending on 
the likelihood of an azole-resistant or echinocandin-resistant 
isolate and the risk of not adequately covering the pathogen. 
For suspicion of invasive mold infection, similar consideration 
can also determine the choice of antifungal. Choice can depend 
on the clinical presentation of the patient and likely focus of 
infection based on symptoms and radiographic data, prior 
prophylactic therapy, serology, and microbiologic/cytologic/
histologic results. Most importantly, the choice of an antifungal 
agent will depend on whether one can exclude or confirm the 
diagnosis of zygomycosis.
Future horizons
New drugs and formulations
A number of new antifungal agents are examined each year. 
Most are studied in vitro or in animal models. However, none 
are in the immediate clinical pipeline. New echinocandins 
and azoles are being developed, such as enfumafungin and 
isavuconazole.133,134 There are also new antifungals with 
novel mechanisms of action. One example is E1210, a 
broad spectrum inhibitor of glycosylphosphatidylinositol 
biosynthesis.135 It was found to inhibit fungal growth and 
biofilm formation, suppress some virulence factors in 
C. albicans, and have in vitro activity against A. fumigatus.136 
Another novel antifungal class includes FG3409, a small 
molecule antifungal with a proprietary “novel mechanism 
of action”. It was found to reduce tissue burden in a murine 
model of disseminated invasive aspergillosis with greater 
potency than the azoles and amphotericin B in vitro.137 It also 
demonstrated greater potency than posaconazole or voricon-
azole against Scedosporium species, including S. prolificans, 
which is often resistant to current commercially available 
antifungals.138 Other novel classes include phosphoinositide-
dependent kinase 1 inhibitors which target the cell wall 
integrity signaling pathway,139 and others that synergize with 
azoles. These include histone deacetylase inhibitors, which 
modulate genes involved in cell wall integrity,140 and type II 
topoisomerase inhibitors.141 In addition to new classes of 
antifungals, novel drug delivery technology has been applied 
to conventional antifungals, such as itraconazole. A nano-
suspension formulation demonstrated improved itraconazole 
activity and less toxicity by eliminating its cardiac inotropic 
effects.142 A new solid oral formulation of posaconazole with 
improved oral bioavailability over the current oral solution 
is currently under investigation.
immunotherapy and vaccines
Despite the development of more active and less toxic 
antifungal agents, mortality rates for invasive fungal infec-
tion remain unacceptably high. There is a need for different 
approaches to both treatment and prevention. Recent efforts 
have focused on immunotherapy and vaccines.143
In general, the primary protective defense mechanism 
against invasive fungal infection is T cell-mediated   immunity, 
specifically, a robust Th1 response to fungal antigens.144 
In the immunocompromised host at risk of invasive fungal 
infection, T cell immunity is compromised due to a number 
of factors, including corticosteroid therapy. Cenci et al 
first demonstrated that passively transferred Aspergillus-
specific Th1-committed CD4+ T cells could protect animals Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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against invasive aspergillosis.145 Beck et al has shown that 
Aspergillus-specific CD4+ T cells can be identified and 
expanded ex vivo to adequate numbers for infusion into 
patients.146 Recently, Perruccio et al demonstrated use of 
Aspergillus-specific immunotherapy in hematopoietic cell 
transplantation that provided rapid immune recovery.147
Vaccination to prevent invasive fungal infection in the 
immunocompromised host is a relatively new concept. It was 
not even attempted because of the assumption that severely 
immunocompromised patients (eg, hematopoietic cell trans-
plantation recipients) cannot be vaccinated effectively within 
a year after their transplant.39,147 However, it was demon-
strated in an animal model that a crude Aspergillus vaccine 
administered before immunosuppression (neutropenia or 
corticosteroid therapy) protected against subsequent invasive 
aspergillosis.145,148 Efforts are now focused on identifying 
epitope(s) with T cell immunogenic and protective properties. 
Also, work on adjuvants149 and dendritic cell vaccination150 
have demonstrated promising results. Finally, there have been 
efforts toward developing Candida vaccines, and these has 
been thoroughly reviewed recently.151
Conclusion
Over the past 20 years, the number of invasive fungal infec-
tions has continued to persist, due primarily to the increased 
numbers of patients we subject to severe immunosuppression. 
Despite the development of more active and less toxic anti-
fungal agents and the standard use of antifungal prophylaxis, 
invasive fungal infection (especially invasive mold infection) 
continues to be a significant factor in hematopoietic cell 
and solid organ transplantation outcomes, resulting in high 
mortality rates. Since the advent of fluconazole as standard 
prophylaxis in the hematopoietic cell transplant setting, inva-
sive candidiasis has come under control, but no mold-active 
antifungal agent (except for posaconazole in the acute myel-
ogenous leukemia/myelodysplastic syndrome setting) has 
been shown to improve on the survival rate over fluconazole. 
With the introduction of new azole and echinocandin agents, 
we have seen the emergence of more azole-resistant and 
  echinocandin-resistant fungi. The recent increase in zygomy-
cosis seen in the hematopoietic cell transplant setting may be 
due to the increased use of voriconazole. This has implications 
for the empiric approach to pulmonary invasive mold infection 
when zygomycosis cannot be ruled out. It is imperative that 
an amphotericin B product, an antifungal that in over 50 years 
has never developed resistance, be initiated.
The clinical presentations of invasive mold infection and 
invasive candidiasis can be nonspecific and the diagnostic 
tests insensitive, so a high index of suspicion and immediate 
initiation of empiric therapy is required. Unfortunately, our 
currently available serologic tests do not predict infection 
ahead of disease, and, therefore, cannot be used to initiate 
“preemptive” therapy. Furthermore, the AGM test gives 
a false negative result in patients receiving antimold pro-
phylaxis, ie, virtually all of our patients with hematologic 
malignancy and hematopoietic cell transplant recipients. We 
may eventually be able to select patients at highest risk for 
invasive fungal infections for prophylaxis by genetic testing. 
However, with our current armamentarium of antifungal 
agents and widespread use of prophylaxis in high-risk groups 
(hematologic malignancy, hematopoietic cell transplanta-
tion), we continue to see high incidence and mortality rates, 
and our future hope lies in reversing immunosuppression or 
augmenting the immune system in these severely immuno-
compromised hosts by developing and utilizing immuno-
therapy, immunoprophylaxis, and vaccines.
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